NCT05722925View on ClinicalTrials.gov

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions

Prostate Cancer

Interventions

DRUG

Fluciclovine PET/CT

8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

Blue Earth Diagnostics

All Listed Sponsors

collaborator

Blue Earth Diagnostics

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT05722925 - Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | Biotech Hunter | Biotech Hunter